Trial Profile
A Phase 1 Dose Escalation and Phase 2 Randomized Double-Blind Study of Veliparib in Combination With Carboplatin and Etoposide as a Therapy of Treatment-Naïve Extensive Stage Disease Small Cell Lung Cancer
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 12 May 2021
Price :
$35
*
At a glance
- Drugs Veliparib (Primary) ; Carboplatin; Etoposide
- Indications Small cell lung cancer; Solid tumours
- Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
- Sponsors AbbVie; AbbVie Germany
- 04 May 2021 Primary endpoint (progression-free survival (PFS)) has been met, according to the results published in the Clinical Cancer Research.
- 04 May 2021 Results (n=181; data cut off date: 14 Sept, 2018) of veliparib plus platinum chemotherapy followed by veliparib maintenance demonstrated improved PFS as first-line treatment for ED-SCLC, published in the Clinical Cancer Research.
- 17 Apr 2019 Status changed from active, no longer recruiting to completed.